Search FEMY
Femasys Inc.
NasdaqCM · CIK 1339005
Last close2.05
Daily change-0.05 (-2.38%)
10 Years gain-99.15%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
FEMY · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
62.9Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue6
Quarterly Revenue23
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth20.2 / 25
Quality12.4 / 25
Capital Efficiency2.2 / 20
Balance Sheet15.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 278.1879 percentage points.
Share count reductionDiluted share count declined 86.6512%.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 5.9723 percentage points.
Key Metrics
Revenue Growth TTM11.54%OK
Revenue CAGR 3Y23.88%OK
Gross Margin60.27%OK
Operating Margin-886.09%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-3,473.47%OK
Incremental Operating Margin 3Y-702.72%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-86.65%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $2.29M | $1.42M | -$17.59M | -$18.69M | -$19.22M | 61.96% | -766.95% | -837.9% | n/a | 39.55M |
| 2025 FY Dec 31, 2024 | $1.63M | $1.08M | -$17.79M | -$19.44M | -$20.21M | 66.55% | -1,091.75% | -1,240.29% | n/a | 22.27M |
| 2024 FY Dec 31, 2023 | $1.07M | $691,901.00 | -$14.51M | -$11.28M | -$11.42M | 64.54% | -1,353.43% | -1,065.74% | n/a | 15.38M |
| 2023 FY Dec 31, 2022 | $1.21M | $764,280.00 | -$11.60M | -$10.73M | -$11.14M | 63.36% | -961.71% | -923.5% | -478.56% | 11.82M |
| 2022 FY Dec 31, 2021 | $1.18M | $809,305.00 | -$8.34M | -$7.93M | -$8.24M | 68.6% | -706.7% | -698.29% | n/a | 6.71M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.90M | sum latest 4 fiscal quarters Revenue | OK | 0001140361-26-033157, 0001140361-25-042308 |
| Revenue Growth TTM | 11.54% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001140361-26-033157, 0001140361-25-042308 |
| Revenue CAGR 3Y | 23.88% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001140361-26-012375 |
| Revenue CAGR 5Y | 17.18% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001140361-26-012375 |
| Gross Profit CAGR 3Y | 22.96% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001140361-26-012375 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001140361-26-033157, 0001140361-25-042308 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 60.27% | Gross Profit / Revenue | OK | 0001140361-26-033157, 0001140361-25-042308 |
| Operating Margin | -886.09% | Operating Income / Revenue | OK | 0001140361-26-033157, 0001140361-25-042308 |
| ROIC | -3,473.47% | NOPAT / Average Invested Capital | OK | 0001140361-26-033157, 0001140361-25-042308 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001140361-26-033157 |
| Current Ratio | 2.14x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.56 | Revenue / Diluted Shares | OK | 0001140361-26-033157, 0001140361-25-042308 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |